Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ASND Ascendis Pharma A/S monthly Stock Chart
ASND [NASD]
Ascendis Pharma A/S
Healthcare | Biotechnology | Denmark
statements
Index- P/E- EPS (ttm)-5.29 Insider Own1.36% Shs Outstand47.99M Perf Week-0.58%
Market Cap7.12B Forward P/E- EPS next Y-4.77 Insider Trans0.00% Shs Float6.00M Perf Month11.75%
Income-252.20M PEG- EPS next Q-1.43 Inst Own- Short Float32.67% Perf Quarter9.77%
Sales11.30M P/S629.78 EPS this Y-48.00% Inst Trans-0.31% Short Ratio7.90 Perf Half Y31.94%
Book/sh12.67 P/B11.52 EPS next Y1.00% ROA-32.50% Target Price181.60 Perf Year12.66%
Cash/sh12.14 P/C12.02 EPS next 5Y24.00% ROE-36.70% 52W Range90.06 - 150.00 Perf YTD4.95%
Dividend- P/FCF- EPS past 5Y-61.90% ROI-35.70% 52W High-2.66% Beta0.97
Dividend %- Quick Ratio13.20 Sales past 5Y-0.90% Gross Margin- 52W Low62.13% ATR4.73
Employees330 Current Ratio13.20 Sales Q/Q-59.30% Oper. Margin- RSI (14)64.50 Volatility1.81% 3.54%
OptionableYes Debt/Eq0.07 EPS Q/Q-6.70% Profit Margin- Rel Volume0.32 Prev Close146.00
ShortableYes LT Debt/Eq0.06 EarningsMay 19 AMC Payout- Avg Volume248.18K Price146.01
Recom1.50 SMA202.42% SMA5011.79% SMA20020.33% Volume80,297 Change0.01%
Mar-20-20Initiated Oppenheimer Outperform $199
Oct-11-19Initiated Morgan Stanley Overweight $128
Mar-25-19Initiated Evercore ISI Outperform
Jan-24-19Upgrade Leerink Partners Mkt Perform → Outperform
Jan-24-19Initiated Cantor Fitzgerald Overweight $102
Jun-26-18Initiated Stifel Buy $85
Apr-02-18Reiterated Leerink Partners Mkt Perform $37 → $64
May-11-17Initiated JP Morgan Overweight $36
Mar-09-17Downgrade Leerink Partners Outperform → Mkt Perform
Feb-09-17Initiated Credit Suisse Outperform $28
Sep-26-16Initiated Wedbush Outperform $34
Jun-03-20 03:46PM  
Should You Avoid Ascendis Pharma A/S (ASND)?
Insider Monkey
May-29-20 09:28PM  
Merit Medical Reaches Deal With Starboard Value
Barrons.com
May-22-20 06:14AM  
Earnings Beat: Ascendis Pharma A/S (NASDAQ:ASND) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St.
May-19-20 04:01PM  
Ascendis Pharma A/S Reports First Quarter 2020 Financial Results
GlobeNewswire
02:30PM  
Ascendis Pharma A/S to Host Earnings Call
ACCESSWIRE
May-11-20 08:30AM  
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer
GlobeNewswire
May-08-20 11:46AM  
7 Strong Buy Healthcare Stocks to Buy Now
InvestorPlace
May-07-20 04:01PM  
Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19
GlobeNewswire
Apr-21-20 06:01AM  
Ascendis Pharma A/S (NASDAQ:ASND) Analysts Just Slashed This Year's Revenue Estimates By 12%
Simply Wall St. -5.84%
Apr-19-20 04:00PM  
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon PTH as a Replacement Therapy for Hypoparathyroidism
GlobeNewswire
Apr-16-20 09:40PM  
Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents
Apr-15-20 04:58PM  
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon hGH as Treatment for Growth Hormone Deficiency in the United States
GlobeNewswire
Apr-01-20 04:01PM  
Ascendis Pharma A/S Reports Full-Year 2019 Financial Results
GlobeNewswire
Mar-25-20 04:01PM  
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1
GlobeNewswire
Mar-22-20 08:25PM  
Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
Insider Monkey
Mar-21-20 08:49AM  
We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely
Simply Wall St.
Mar-17-20 12:00PM  
Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade
Zacks
Feb-12-20 04:01PM  
Ascendis Pharma A/S Announces Upcoming Investor Presentation in February
GlobeNewswire
Feb-10-20 09:28AM  
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
Zacks
Feb-06-20 10:44AM  
Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?
Zacks
Feb-04-20 11:28AM  
Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter
GuruFocus.com
Jan-21-20 05:21AM  
Shareholders Are Raving About How The Ascendis Pharma (NASDAQ:ASND) Share Price Increased 554%
Simply Wall St.
Jan-12-20 07:45PM  
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
Jan-09-20 04:00PM  
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
Dec-26-19 11:26AM  
How Did Ascendis Pharma A/S (ASND) Compare Against Hedge Fund Darlings in 2019?
Insider Monkey
Dec-06-19 11:57PM  
Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT
Thomson Reuters StreetEvents
Dec-04-19 12:42PM  
Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND)
Insider Monkey
Nov-22-19 05:38AM  
Ascendis Pharma A/S Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Simply Wall St.
Nov-21-19 09:05AM  
Top Ranked Momentum Stocks to Buy for November 21st
Zacks
Nov-18-19 04:01PM  
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results
GlobeNewswire
10:33AM  
Top Ranked Momentum Stocks to Buy for November 18th
Zacks
01:02AM  
New Records and New Milestones
Zacks
Nov-14-19 04:01PM  
Ascendis Pharma Expands TransCon PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
GlobeNewswire
Nov-12-19 09:52AM  
What's in Store for Helmerich & Payne (HP) in Q4 Earnings?
Zacks
Nov-11-19 07:50AM  
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Zacks
Nov-08-19 04:02PM  
Ascendis Pharma A/S Announces Upcoming Investor Presentation in November
GlobeNewswire
Nov-06-19 04:02PM  
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon Technology in Oncology at SITC 2019
GlobeNewswire
Nov-05-19 11:50AM  
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
Zacks
11:13AM  
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
Zacks
Nov-04-19 06:30PM  
Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18
GlobeNewswire
Oct-29-19 09:00AM  
Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why
Zacks
Oct-24-19 11:47AM  
How to invest in biotech stocks like a Nobel Prize winner
MarketWatch
Oct-21-19 04:04PM  
Ascendis Pharma A/S Receives Orphan Designation for TransCon hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe
GlobeNewswire
Oct-14-19 08:44PM  
Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND)
Insider Monkey
Oct-01-19 03:50PM  
Edited Transcript of ASND earnings conference call or presentation 28-Aug-19 8:30pm GMT
Thomson Reuters StreetEvents
Sep-26-19 08:25AM  
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October
GlobeNewswire -6.52%
Sep-19-19 08:30AM  
When Will Ascendis Pharma A/S (NASDAQ:ASND) Run Out Of Money?
Simply Wall St.
Sep-12-19 04:20PM  
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon CNP at International Skeletal Dysplasia Society Meeting
GlobeNewswire
Sep-03-19 03:20AM  
3 Biopharma Stocks With Over 50% Upside
TipRanks
Aug-29-19 05:15PM  
Ascendis Pharma A/S Announces Three Investor Presentations in September
GlobeNewswire
04:23AM  
Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript
Motley Fool
Aug-28-19 04:01PM  
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
GlobeNewswire
Aug-14-19 05:30PM  
Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28
GlobeNewswire
Jul-18-19 04:12PM  
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon CNP in Children with Achondroplasia
GlobeNewswire
Jun-19-19 08:30AM  
Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs
GlobeNewswire
Jun-10-19 10:10AM  
Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
Insider Monkey
May-31-19 02:02AM  
Edited Transcript of ASND earnings conference call or presentation 30-May-19 8:30pm GMT
Thomson Reuters StreetEvents
May-30-19 04:02PM  
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
GlobeNewswire
02:30PM  
Ascendis Pharma A/S to Host Earnings Call
ACCESSWIRE
May-20-19 07:30AM  
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
GlobeNewswire
May-16-19 08:00AM  
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
GlobeNewswire
May-07-19 04:02PM  
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
GlobeNewswire
12:43PM  
Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap
Insider Monkey
May-06-19 11:09AM  
What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
Simply Wall St.
Apr-29-19 09:28AM  
Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
Insider Monkey
Apr-27-19 08:40AM  
Glenview Capital Managements Stock Pitches At 2018 Sohn Conference
Insider Monkey
Apr-24-19 05:26PM  
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
GlobeNewswire
Apr-23-19 08:59AM  
Joseph Jolsons Harvest Capital Strategies Return, AUM, and Holdings
Insider Monkey
Apr-20-19 12:25PM  
Best Stock Pick From The 2018 Sohn Conference (Part II)
Insider Monkey
Apr-15-19 01:21PM  
Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT
Thomson Reuters StreetEvents
Apr-11-19 01:11AM  
What Happened With Light Streets Glen Kachers Best Idea at 2018 Sohn Conference?
Insider Monkey
Apr-08-19 01:06PM  
Mangrove Partners Nathaniel Augusts Best Idea At 2018 Sohn Conference
Insider Monkey
Apr-07-19 11:59PM  
Sarissa Capital Management Hires New President
Insider Monkey
Apr-04-19 01:14AM  
Ascendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call Transcript
Motley Fool
Apr-03-19 04:01PM  
Ascendis Pharma A/S Reports Full Year 2018 Financial Results
GlobeNewswire
02:30PM  
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call
ACCESSWIRE
Mar-27-19 05:00PM  
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
GlobeNewswire
Mar-25-19 02:45PM  
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
Zacks
02:00PM  
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
GlobeNewswire
Mar-24-19 12:45PM  
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone
GlobeNewswire
Mar-14-19 01:08PM  
ValueAct Capitals CBRE Recommendation Delivers 150% Gain
Insider Monkey
Mar-12-19 10:56AM  
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
Zacks
Mar-07-19 07:10AM  
Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries New Horizons, Emerging Trends, and Upcoming Developments
GlobeNewswire
Mar-06-19 02:31PM  
Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%
Simply Wall St. -8.53%
10:00AM  
Under the Radar Cannabis Stock-THC Therapeutics, Inc.
ACCESSWIRE
04:05AM  
Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS
Benzinga
Mar-05-19 08:07PM  
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
GlobeNewswire
09:43AM  
Company News For Mar 5, 2019
Zacks
Mar-04-19 04:01PM  
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
GlobeNewswire +74.00%
06:30AM  
Ascendis Pharma Announces Once-weekly TransCon Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
GlobeNewswire
Feb-28-19 08:20PM  
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
GlobeNewswire
07:45AM  
Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences Renewed Outlook, Key Drivers of Growth
GlobeNewswire
Feb-13-19 09:53AM  
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
Zacks
Feb-11-19 05:27PM  
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
GlobeNewswire
Jan-25-19 09:18AM  
All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy
Zacks
Jan-17-19 12:29PM  
Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT
Thomson Reuters StreetEvents
Jan-07-19 09:00AM  
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
GlobeNewswire
Dec-21-18 04:01PM  
Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference
GlobeNewswire -7.58%
Dec-12-18 02:57AM  
Should You Buy Ascendis Pharma A/S (ASND)?
Insider Monkey
Nov-28-18 11:03PM  
Ascendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript
Motley Fool
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
open in yahoo | open in reuters | open in google